Pexelizumab may be hazardous to those with ST-segment elevation myocardial infarction undergoing primary percutaneous interventions without using glycoprotein IIb-IIIa inhibitors.
Gen-Min
GM
Lin
Kai-Min
KM
Chu
Chih-Lu
CL
Han
D015906:Angioplasty, Balloon, Coronary / Q000401:mortality*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D003182:Complement C5 / Q000276:immunology; D000075202:Contraindications; D004359:Drug Therapy, Combination; D004562:Electrocardiography; D006801:Humans; D009203:Myocardial Infarction / Q000175:diagnosis / Q000401:mortality* / Q000628:therapy; D015428:Myocardial Reperfusion Injury / Q000188:drug therapy / Q000401:mortality*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D057127:Single-Chain Antibodies / Q000009:adverse effects*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003182:Complement C5; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D057127:Single-Chain Antibodies; C402724:pexelizumab